Journal of Medicinal Chemistry · 2015 · 24 citations · 51 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryNeurochemistryNeuropharmacologyEnzyme InhibitionNeurochemical PharmacologyActive Site MechanismsAgonist ActivityAmino AcidsN-methyl-d-aspartate Receptor InhibitionNmda Receptor FunctionNmda Receptor PharmacologyNmda Receptors
D-Aspartate oxidase (DDO) is a degradative enzyme that is stereospecific for acidic D-amino acids, including D-aspartate, a potential agonist of the N-methyl-D-aspartate (NMDA) receptor. Dysfunction of NMDA receptor-mediated neurotransmission has been implicated in the onset of various mental disorders, such as schizophrenia. Hence, a DDO inhibitor that increases the brain levels of D-aspartate and thereby activates NMDA receptor function is expected to be a useful compound. To search for potent DDO inhibitor(s), a large number of compounds were screened in silico, and several compounds were identified as candidates. They were then characterized and evaluated as novel DDO inhibitors in vitro (e.g., the inhibitor constant value of 5-aminonicotinic acid for human DDO was 3.80 μM). The present results indicate that some of these compounds may serve as lead compounds for the development of a clinically useful DDO inhibitor and as active site probes to elucidate the structure-function relationships of DDO.
51
Long-term potentiation depends on release of d-serine from astrocytes
Christian Henneberger, Thomas Papouin, Stéphane H. R. Oliet et al. · Nature · 2010 · 1.4K citations · Full text
Glia-Derived d-Serine Controls NMDA Receptor Activity and Synaptic Memory
Aude Panatier, Dionysia T. Theodosis, Jean‐Pierre Mothet et al. · Cell · 2006 · 904 citations · Full text
H. A. Krebs · Biochemical Journal · 1935 · 776 citations · Full text